根据2024癌症免疫治疗学会(SITC)年会上公布的II期THIO-101试验(NCT05208944)的结果,首创的端粒靶向药物THIO与cemiplimab联合使用在检查点抑制剂耐药的晚期非小细胞肺癌(NSCLC)患者中显示出持久活性,较高的疾病控制率(DCR)和生存获益。采用18...
Nov. 9, 2024 (session time subject to change). An abstract submitted for a YIA that does not receive an award may still be accepted as an abstract for SITC 2024 and will be considered a Regular Abstract.
Dostarlimab生存疗效优于Pembrolizumab 2024年SITC年会上公布了PERLA2期试验的更新结果,港安健康国际医疗介绍,在晚期非小细胞肺癌(NSCLC)患者的一线治疗中,与Pembrolizumab(Keytruda)加化疗相比,免疫治疗Dostarlimab联合化疗改善了晚期NSCLC患者的总生存期,中位生存期为20.2个月对15.9个月。 港安健康补充阅读: 香港进口免...
PERLA试验结果显示:与帕博利珠单抗相比,Dostarlimab联合化疗在晚期NSCLC中显示出更好的总生存,中位OS为20.2个月 vs 15.9个月。 试验的主要终点是客观缓解率,次要终点包括总生存、无进展生存和安全性。 PERLA试验的OS结果显示,Dostarlimab联合...
Updated overall survival from PERLA a phase II randomized double-blind trial of dostarlimab+chemotherapy vs pembrolizumab+chemotherapy in metastatic non-squamous non-small cell lung cancer.Presented at the 2024 Society for Immunotherapy of Cancer Annual Meeting;November 6-10,2024;Houston,TX.Abstract ...
苏州2024年11月11日 /美通社/ -- 康宁杰瑞生物制药(股票代码:9966.HK)宣布,HER2双特异性抗体偶联药物(ADC)与PD-L1抑制剂的高浓度皮下注射复方制剂JSKN033的首次人体临床研究结果入选2024年第39届癌症免疫治疗学会(Society for Immunotherapy of Cancer, SITC)年会最新突破性摘要(Late-Breaking Abstract, LBA),于会...
2024年11月11日,中国苏州,康宁杰瑞生物制药(股票代码:9966.HK)宣布,HER2双特异性抗体偶联药物(ADC)与PD-L1抑制剂的高浓度皮下注射复方制剂JSKN033的首次人体临床研究结果入选2024年第39届癌症免疫治疗学会(Society for Immunotherapy of Cancer, SITC)年会最新突破性摘要(Late-Breaking Abstract, LBA),于会议期间以...
Abstract #1406: A Novel PTK7-Directed Antibody-Drug Conjugate (ADC) PRO1107 Demonstrated Broad Antitumor Activity with a Promising Safety Profile in Preclinical Models Presented byZhu Chen, Ph.D., ProfoundBio Chief Scientific Officer, onSaturday, November 4, 2023, Exhibit Halls A and B1, 9 a....
Abstract Number:301 ASH 2024 Poster Presentations Title:Late Polyclonal P-BCMA-101 CAR-T Cell Re-expansion and Rapid Complete Response in a Patient with Relapsed Multiple Myeloma Treated with One Cycle of Talquetamab, More Than 3 Year...
SITC 2024 abstract Data cut off: May 16, 2024 Note: The poster to be presented at SITC on November 8, 2024 will include additional data Treatment COM701+COM902+pembrolizumab No. patients 23 (efficacy evaluable) Confirmed ORR 17.4% (1 CR, 3 PR) Confirmed DCR 43.5 % ...